Consensus Jasper Therapeutics, Inc.

Stocks

JSPR

US4718712023

Biotechnology & Medical Research

Market Closed - Nasdaq 00:00:00 29/10/2026 +04			5-day change	1st Jan Change
0.5388 ^USD	+3.84%		+6.84%	-70.56%

10-15	Jasper Therapeutics, Inc. Completes Enrollment of Iga Nephropathy Cohort of Phase 2 Basket Study Evaluating Vensobafusp Alfa	CI
09-29	Jasper Therapeutics, Inc. Announces CFO Changes, Effective October 9, 2026	CI

Evolution of the Average Target: Jasper Therapeutics, Inc.

Evolution of the Target Price: Jasper Therapeutics, Inc.

Changes in Analyst Recommendations: Jasper Therapeutics, Inc.

3cc5f8.xWXJx5rmgm-SKNXlnRAUpVeW0Dd5VeiVB1Z8xgMTz5g.swCujNm090L-YODdrShi-jX-iG00BL3YPglN8Wh3-v7xAaGw1JLdJ6ZyhA~6503c2ddd7206d742d58f09ec89b5f32

Analysts' recommendations: Jasper Therapeutics, Inc.

08-12	Piper Sandler Initiates Jasper Therapeutics With Overweight Rating, $2 Price Target	MT
05-15	RBC Cuts Price Target on Jasper Therapeutics to $3 From $4, Keeps Sector Perform, Speculative Risk	MT
05-15	TD Cowen Downgrades Jasper Therapeutics to Hold From Buy	MT
03-23	UBS Downgrades Jasper Therapeutics To Neutral From Buy, Cuts Price Target to $1.5 From $25	MT
11-11	RBC Cuts Price Target on Jasper Therapeutics to $4 From $5, Keeps Sector Perform, Speculative Risk	MT
11-10	Jasper Therapeutics Q3 loss smaller than estimates	RE
15/08/25	UBS Cuts Price Target on Jasper Therapeutics to $25 From $29, Maintains Buy Rating	MT
08/07/25	BMO Capital Downgrades Jasper Therapeutics to Market Perform From Outperform, Cuts Price Target to $4 From $15	MT
08/07/25	RBC Downgrades Jasper Therapeutics to Sector Perform From Outperform, Cuts Price Target to $5 From $46; Speculative Risk Kept	MT
07/07/25	Cantor Fitzgerald Downgrades Jasper Therapeutics to Neutral From Overweight; Shares Plunge	MT
07/07/25	William Blair Downgrades Jasper Therapeutics to Market Perform From Outperform	MT
07/07/25	HC Wainwright Adjusts Price Target on Jasper Therapeutics to $20 From $40, Maintains Buy Rating	MT
15/05/25	Oppenheimer Cuts Price Target on Jasper Therapeutics to $65 From $80, Keeps Outperform Rating	MT
13/05/25	UBS Adjusts Price Target on Jasper Therapeutics to $33 From $38, Maintains Buy Rating	MT
13/05/25	RBC Adjusts Price Target on Jasper Therapeutics to $46 From $48, Maintains Outperform Speculative Risk Rating	MT
09/01/25	RBC Cuts Price Target on Jasper Therapeutics to $48 From $68, Keeps Outperform, Speculative Risk	MT
09/09/24	JMP Securities Initiates Coverage on Jasper Therapeutics With Market Outperform Rating, $70 Price Target	MT
08/07/24	BTIG Initiates Jasper Therapeutics at Buy With $90 Price Target	MT
27/06/24	Stifel Initiates Jasper Therapeutics at Buy With $86 Price Target	MT
06/05/24	HC Wainwright Starts Jasper Therapeutics With Buy Rating, $65 Price Target	MT
03/04/24	Evercore ISI Initiates Jasper Therapeutics With Outperform Rating, Price Target is $65	MT
28/03/24	Jasper Therapeutics Initiated at Outperform, Speculative Risk by RBC, Price Target Set at $70 Amid Bullish View on Lead Asset	MT
18/03/24	TD Cowen Initiates Jasper Therapeutics With Outperform Rating	MT
11/08/23	Capital One Initiates Jasper Therapeutics With Overweight Rating, $7 Price Target	MT
25/05/23	EF Hutton Assumes Jasper Therapeutics at Buy With $6.85 Price Target	MT

More recommendations

Bio Therapeutic Drugs

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
JASPER THERAPEUTICS, INC.	-	-	-	-	+3,754.31%
WUXI APPTEC CO., LTD.					+41.32%
ARGENX SE					+28.63%
LONZA GROUP AG					+9.56%
IQVIA HOLDINGS INC.					+12.15%
BEONE MEDICINES AG					+19.23%
REVOLUTION MEDICINES, INC.					+39%
CELLTRION, INC.					+42.31%
GENMAB A/S					+6.5%
WUXI BIOLOGICS (CAYMAN) INC.					+35.02%
Average					+398.80%
Weighted average by Cap.					+26.36%